250 related articles for article (PubMed ID: 15896756)
1. Extended ganciclovir prophylaxis in lung transplantation.
Perreas KG; McNeil K; Charman S; Sharples LD; Wreghitt T; Wallwork J
J Heart Lung Transplant; 2005 May; 24(5):583-7. PubMed ID: 15896756
[TBL] [Abstract][Full Text] [Related]
2. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.
Soghikian MV; Valentine VG; Berry GJ; Patel HR; Robbins RC; Theodore J
J Heart Lung Transplant; 1996 Sep; 15(9):881-7. PubMed ID: 8889983
[TBL] [Abstract][Full Text] [Related]
3. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
Ruttmann E; Geltner C; Bucher B; Ulmer H; Höfer D; Hangler HB; Semsroth S; Margreiter R; Laufer G; Müller LC
Transplantation; 2006 May; 81(10):1415-20. PubMed ID: 16732179
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation.
Hertz MI; Jordan C; Savik SK; Fox JM; Park S; Bolman RM; Dosland-Mullan BM
J Heart Lung Transplant; 1998 Sep; 17(9):913-20. PubMed ID: 9773865
[TBL] [Abstract][Full Text] [Related]
5. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.
Valentine VG; Weill D; Gupta MR; Raper B; Laplace SG; Lombard GA; Bonvillain RW; Taylor DE; Dhillon GS
J Heart Lung Transplant; 2008 Aug; 27(8):875-81. PubMed ID: 18656801
[TBL] [Abstract][Full Text] [Related]
6. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation.
Westall GP; Michaelides A; Williams TJ; Snell GI; Kotsimbos TC
Transplantation; 2003 Jun; 75(12):2064-8. PubMed ID: 12829913
[TBL] [Abstract][Full Text] [Related]
7. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.
Heng D; Sharples LD; McNeil K; Stewart S; Wreghitt T; Wallwork J
J Heart Lung Transplant; 1998 Dec; 17(12):1255-63. PubMed ID: 9883768
[TBL] [Abstract][Full Text] [Related]
8. Are heart-lung transplant recipients protected from developing bronchiolitis obliterans syndrome?
Moffatt-Bruce SD; Karamichalis J; Robbins RC; Whyte RI; Theodore J; Reitz BA
Ann Thorac Surg; 2006 Jan; 81(1):286-91; discussion 291. PubMed ID: 16368382
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
10. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J
Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden.
Johanssson I; Mårtensson G; Andersson R
Scand J Infect Dis; 2010; 42(2):129-36. PubMed ID: 20082575
[TBL] [Abstract][Full Text] [Related]
13. Infections in lung allograft recipients: ganciclovir era.
Valentine VG; Bonvillain RW; Gupta MR; Lombard GA; LaPlace SG; Dhillon GS; Wang G
J Heart Lung Transplant; 2008 May; 27(5):528-35. PubMed ID: 18442719
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients.
Danziger-Isakov LA; DelaMorena M; Hayashi RJ; Sweet S; Mendeloff E; Schootman M; Huddleston CB; DeBaun MR
Transplantation; 2003 May; 75(9):1538-43. PubMed ID: 12792511
[TBL] [Abstract][Full Text] [Related]
15. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.
Johansson I; Mårtensson G; Nyström U; Nasic S; Andersson R
BMC Infect Dis; 2013 Dec; 13():582. PubMed ID: 24325216
[TBL] [Abstract][Full Text] [Related]
16. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
Israni A; Krok K; Cohen D; Blumberg E; Bloom RD
Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
[TBL] [Abstract][Full Text] [Related]
17. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.
Chmiel C; Speich R; Hofer M; Michel D; Mertens T; Weder W; Boehler A
Clin Infect Dis; 2008 Mar; 46(6):831-9. PubMed ID: 18269330
[TBL] [Abstract][Full Text] [Related]
18. Redo lung transplantation: a North American-European experience.
Novick RJ; Kaye MP; Patterson GA; Andréassian B; Klepetko W; Menkis AH; McKenzie FN
J Heart Lung Transplant; 1993; 12(1 Pt 1):5-15; discussion 15-6. PubMed ID: 8382951
[TBL] [Abstract][Full Text] [Related]
19. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
[TBL] [Abstract][Full Text] [Related]
20. Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts.
Tikkanen JM; Kallio EA; Bruggeman CA; Koskinen PK; Lemström KB
Am J Respir Crit Care Med; 2001 Aug; 164(4):672-9. PubMed ID: 11520736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]